Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: TNFAIP3

Summary for TNFAIP3

Gene information	Gene symbol	TNFAIP3
	Ensembl ID	ENSG00000118503
	Entrez ID	7128
	Gene name	TNF alpha induced protein 3
	Synonyms	A20\|OTUD7C
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: TNFAIP3

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.747342	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.414122	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.347153	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.599642	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.463018	1.70e-43
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.396846	5.29e-16
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.443876	1.47e-07
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.847942	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.697532	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.687679	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Mono/Macro	-1.73748	4.37e-03
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.85837	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.311633	1.67e-42
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.58881	1.16e-03
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.942496	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.52353	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.318543	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.4448	8.88e-05
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.956224	4.44e-13
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	B cells	-1.1624	2.85e-05
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.63444	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-2.22565	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.344239	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.66443	3.10e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.906122	2.71e-29
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mast cells	2.36548	3.46e-04
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	1.01918	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.725795	3.81e-30
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	Mono/Macro	-0.368792	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-0.370584	7.81e-41
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	-0.464238	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	1.41372	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	1.06535	4.69e-18
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	1.07927	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.694996	2.65e-09
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.342659	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.4918	2.97e-27
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.584037	6.27e-39
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.489085	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.371262	8.95e-04
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	cDCs	0.3088	3.54e-02
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.475864	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	NK cells	-0.298706	9.50e-04
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.705504	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.781471	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.836646	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.89451	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	1.11106	2.48e-35
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.683518	2.06e-18
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.767862	5.12e-34
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	0.564277	9.84e-12
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.585853	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.504296	3.31e-26
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.691043	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.578908	2.14e-29
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.259802	4.75e-40
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.359042	8.40e-40

Top

Expression of TNFAIP3 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to TNFAIP3

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
TNFAIP3	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating TNFAIP3

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
TNFAIP3	hsa-miR-5692a	99.8167	NM_001270507
TNFAIP3	hsa-miR-23a-3p	97.24	NM_001270507
TNFAIP3	hsa-miR-23c	97.24	NM_001270507
TNFAIP3	hsa-miR-23b-3p	97.24	NM_001270507
TNFAIP3	hsa-miR-18a-5p	94.9976	NM_001270507
TNFAIP3	hsa-miR-18b-5p	94.9976	NM_001270507
TNFAIP3	hsa-miR-4735-3p	94.9976	NM_001270507
TNFAIP3	hsa-miR-4446-5p	94.6922	NM_001270507
TNFAIP3	hsa-miR-19b-3p	94.3388	NM_001270507
TNFAIP3	hsa-miR-19a-3p	94.3388	NM_001270507
TNFAIP3	hsa-miR-7845-5p	93.6028	NM_001270508
TNFAIP3	hsa-miR-2116-5p	91.8016	NM_001270508
TNFAIP3	hsa-miR-141-3p	90.2061	NM_001270507
TNFAIP3	hsa-miR-200a-3p	90.2061	NM_001270507
TNFAIP3	hsa-miR-656-3p	88.2158	NM_001270508
TNFAIP3	hsa-miR-4743-3p	88.1851	NM_001270508
TNFAIP3	hsa-miR-32-3p	87.6895	NM_001270507
TNFAIP3	hsa-miR-29c-3p	87.4084	NM_001270507
TNFAIP3	hsa-miR-29b-3p	87.4084	NM_001270507
TNFAIP3	hsa-miR-29a-3p	87.4084	NM_001270507
TNFAIP3	hsa-miR-4659b-3p	86.9929	NM_001270508
TNFAIP3	hsa-miR-4659a-3p	86.9929	NM_001270508
TNFAIP3	hsa-miR-3978	86.4196	NM_001270508
TNFAIP3	hsa-miR-6837-3p	86.1886	NM_001270507
TNFAIP3	hsa-miR-4795-3p	85.7763	NM_001270507
TNFAIP3	hsa-miR-4319	85.3415	NM_001270507
TNFAIP3	hsa-miR-3124-3p	83.9046	NM_001270508
TNFAIP3	hsa-miR-125a-5p	83.6832	NM_001270507
TNFAIP3	hsa-miR-125b-5p	83.6832	NM_001270507
TNFAIP3	hsa-miR-4635	83.253	NM_001270508
TNFAIP3	hsa-miR-4653-5p	83.0436	NM_001270508
TNFAIP3	hsa-miR-3921	83.0436	NM_001270508
TNFAIP3	hsa-miR-374a-5p	82.9588	NM_001270508
TNFAIP3	hsa-miR-4719	82.7169	NM_001270508
TNFAIP3	hsa-miR-340-5p	82.0877	NM_001270508
TNFAIP3	hsa-miR-374b-5p	81.1846	NM_001270508

Page: 1

Top

Motifs and transcription factors (TFs) regulating TNFAIP3

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
TNFAIP3	hocomoco__SOX9_HUMAN.H11MO.1.B	SOX9 (directAnnotation).
TNFAIP3	transfac_pro__M01252	E2F6 (directAnnotation).
TNFAIP3	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
TNFAIP3	taipale__FOXD3_DBD_RTAAAYA	FOXD3 (directAnnotation).
TNFAIP3	transfac_pro__M04706	RELA (directAnnotation).
TNFAIP3	transfac_pro__M07431	SOX11 (directAnnotation).
TNFAIP3	jaspar__MA0442.2	SOX10 (directAnnotation).
TNFAIP3	hocomoco__FOXP1_HUMAN.H11MO.0.A	FOXP1 (directAnnotation).
TNFAIP3	metacluster_156.2	ATF3; ATF4; ATF4; ATF4; ATF4; ATF4; ATF4; CEBPG; CEBPG; DDIT3; MYC (directAnnotation). ATF4; ATF4; ATF4; CEBPG; DDIT3 (inferredBy_Orthology).
TNFAIP3	metacluster_111.5	E4F1; E4F1 (directAnnotation).
TNFAIP3	transfac_pro__M01861	ATF1 (directAnnotation).
TNFAIP3	tfdimers__MD00192	CHURC1 (directAnnotation).
TNFAIP3	transfac_pro__M05916	ZNF407 (directAnnotation).
TNFAIP3	transfac_pro__M05977	ZNF257 (directAnnotation).
TNFAIP3	transfac_public__M00415	ZEB1 (directAnnotation).
TNFAIP3	swissregulon__hs__SOX10	SOX10 (directAnnotation).
TNFAIP3	homer__GGAAATTCCC_NFkB-p65-Rel	RELA (inferredBy_Orthology).
TNFAIP3	metacluster_130.1	ZNF713; ZNF713 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
TNFAIP3	tfdimers__MD00259	HOXA13; MAFA (directAnnotation).
TNFAIP3	tfdimers__MD00044	ELF1; ELF2; ELF4; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV4; ETV6; ETV7; FLI1; GABPA; GABPB1; SIRT6; SPI1; SPIB (directAnnotation).
TNFAIP3	taipale_tf_pairs__ATF4_TEF_RNMTGATGCAATN_CAP	ATF4; TEF (directAnnotation).
TNFAIP3	transfac_pro__M04860	RXRA (directAnnotation).
TNFAIP3	swissregulon__mm__Atf2	ATF2 (inferredBy_Orthology).
TNFAIP3	metacluster_32.45	HDAC2 (directAnnotation).
TNFAIP3	metacluster_190.7	ILF2; NFATC1; NFATC1; NFATC1; NFATC1; NFATC2; NFATC2; NFATC2; NFATC3; NFATC3; NFATC3; NFATC3; NFATC4; NFATC4; NFATC4 (directAnnotation).
TNFAIP3	hdpi__RAN	RAN (directAnnotation).
TNFAIP3	swissregulon__hs__NFATC2	NFATC2 (directAnnotation).
TNFAIP3	transfac_pro__M01886	NFATC3 (directAnnotation).
TNFAIP3	transfac_pro__M07607	NFATC3 (directAnnotation).
TNFAIP3	hocomoco__PRDM6_HUMAN.H11MO.0.C	PRDM6 (directAnnotation).
TNFAIP3	cisbp__M05891	SOX10 (directAnnotation).
TNFAIP3	transfac_pro__M05380	NR2E1 (inferredBy_Orthology).
TNFAIP3	transfac_pro__M06104	ZNF16 (directAnnotation).
TNFAIP3	tfdimers__MD00012	ETS1; YY1 (directAnnotation).
TNFAIP3	hdpi__PRKRIR	THAP12 (directAnnotation).
TNFAIP3	hdpi__ZNF671	ZNF671 (directAnnotation).
TNFAIP3	cisbp__M00377	POU2F1 (directAnnotation).
TNFAIP3	transfac_pro__M02027	PARP1 (directAnnotation).
TNFAIP3	tfdimers__MD00420	E2F1; PAX4 (directAnnotation).
TNFAIP3	transfac_pro__M03849	SOX4 (directAnnotation).
TNFAIP3	transfac_public__M00148	SRY (directAnnotation).
TNFAIP3	transfac_pro__M03854	SRY (directAnnotation).
TNFAIP3	transfac_pro__M07332	POU3F2 (directAnnotation).
TNFAIP3	transfac_pro__M05768	ZNF544 (directAnnotation).
TNFAIP3	transfac_pro__M05667	ZNF35 (directAnnotation).
TNFAIP3	taipale_tf_pairs__MYBL1_TBX21_AGGTGTGNCSGTTR_CAP_repr	MYBL1; TBX21 (directAnnotation).
TNFAIP3	metacluster_22.18	BACH2 (inferredBy_Orthology).
TNFAIP3	transfac_pro__M04814	RELA (directAnnotation).
TNFAIP3	metacluster_5.1	HIVEP1; HIVEP1; NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; NFKB2; NFKB2; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELA; RELB; RELB (directAnnotation). NFAT5; NFKB1; NFKB1; NFKB1; NFKB1; NFKB1; NFKB2; NFKB2; NFKB2; REL; REL; REL; REL; RELA; RELA; RELA; RELA; RELA; RELB; RELB; RELB (inferredBy_Orthology).
TNFAIP3	transfac_pro__M07066	STAT6 (directAnnotation).

Page: 1 2 3 4 5 6 7 8 9

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."